

**TRI COVID-19 Feasibility Questionnaire**

The Thrombosis Research Institute (TRI) has partnered with Sanofi and are planning to conduct a clinical trial to investigate how early thromboprophylaxis may prevent COVID-19 disease progression and hospital admission.

You have been invited to complete a feasibility questionnaire to express your interest and suitability to take part in this COVID-19 community-based trial. Recent evidence suggests that severe COVID-19 infections are associated with a profound prothrombotic state and large and small vessel thrombosis.

This is now thought to contribute significantly to disease progression and overall morbidity and mortality. We plan to conduct an open-label randomized controlled trial of community-based early thromboprophylaxis with low-molecular-weight heparin (LMWH) versus standard of care in symptomatic participants diagnosed with COVID-19.

We are looking to enrol participants who meet the following criteria: ∙Positive COVID-19 diagnosis and are symptomatic, ∙ Age ≥ 55 year, ∙ 2 additional predefined risk factors. Patients with contraindications to heparins or participating in incompatible interventional study will be excluded. We anticipate that this questionnaire will only take about 10 minutes of your time and look forward to receiving your response.

1.Please indicate if you would be interested in taking part in a TRI sponsored COVID-19 clinical trial.

|  |  |
| --- | --- |
|  | No |
|  | Yes |

More question types

Not available when form is shared externally. Change your setting to "Only people in my organisation can respond"

2.Please enter your email address

|  |
| --- |
|  |

3.Which country is your practice based in?

|  |
| --- |
|  |

4.What is the full name of your practice/hospital?

|  |
| --- |
|  |

5.Have you worked with the Thrombosis Research Institute (TRI) before?

|  |
| --- |
|  |

|  |  |
| --- | --- |
|  | No |
|  | Yes |

Required to answer

6. Please select all the studies you have worked with TRI

|  |  |
| --- | --- |
|  | Breach |
|  | Garfield AF |
|  | Garfield VTE |
|  | Gastronox |
|  | PERCEIVE |
|  | RIVER |

7.Who is/are the principal investigator(s) of your study/studies?

|  |
| --- |
|  |

8.What type of setting is your practice?

Required to answer

|  |  |
| --- | --- |
|  | Hospital - Public |
|  | Hospital - Private |
|  | Office - Group |
|  | Office - Solo |
|  | Other |

9.How many randomised clinical trials (RCTs) have you conducted in the past 5 years?

|  |
| --- |
|  |

10.How many randomised clinical trials (RCTs) are you currently conducting?

|  |
| --- |
|  |

Required to answer

11.Does your practice have capacity to take part in a randomised clinical trials at present?

Required to answer

|  |  |
| --- | --- |
|  | No |
|  | Yes |

12.In relation to the above question, please add any additional information or comments. (Optional)

|  |
| --- |
|  |

13.Does your practice have staff that are qualified to dispense, manage and store investigational product (IP)/study drug? The IP for this trial is low-molecular-weight heparin (LMWH).

|  |  |
| --- | --- |
|  | No |
|  | Yes |

Required to answer

14. In relation to the above question, please add any additional information or comments. (Optional)

|  |
| --- |
|  |

15.Please provide an estimate of the number of confirmed COVID-19 cases that your practice is currently treating per week.

|  |
| --- |
|  |

16.How are suspected COVID-19 cases reported to you? Please tick all options that apply.

|  |  |
| --- | --- |
|  | patient via phone |
|  | patient in person at your practice  |
|  | community centre (you see them there or they are referred to you) |
|  | testing centre (you see them there or they are referred to you) |
|  | hospital (you see them there or they are referred to you) |
|  | referred to you by a laboratory |
|  | other |